Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

PRNewsWire

17 Jul 2026, 05:22 UTC · 1h ago

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

What the story claims

3 claims · each scored for market impact

What matters in this story

1
The US FDA has accepted the resubmission of Camurus' New Drug Application (NDA) for CAM2029 to treat acromegaly. — Acceptance for review is a critical regulatory milestone that moves the company closer to US market entry and revenue generation.
+0.60
2
The previous Complete Response Letter (CRL) was based on manufacturing site observations and did not concern the drug's clinical efficacy or safety. — De-risks the application by confirming that the primary hurdle was operational (cGMP) rather than a fundamental failure of the drug's performance.
+0.40
3
The FDA has set a PDUFA target action date for the CAM2029 application for December 18, 2026. — Provides a concrete timeline for a potential binary catalyst event (approval or rejection) which allows investors to price in expectations.
+0.30

Which stocks this story touches

6 related stories

GlobeNewsWire
5h ago
Kuehn Law Encourages Investors of Quantum Computing Inc. to Contact Law Firm
- biotech
- pharmaceuticals
Read

Camurus' NDA resubmission… — CAMX +0.60 | NewsImpactScreener

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

What matters in this story

Kuehn Law Encourages Investors of Quantum Computing Inc. to Contact Law Firm

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

What matters in this story

Kuehn Law Encourages Investors of Quantum Computing Inc. to Contact Law Firm

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

ROSEN, LEADING TRIAL ATTORNEYS, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GRAL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

What matters in this story

Next reads from the same story arc

Kuehn Law Encourages Investors of Quantum Computing Inc. to Contact Law Firm

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

What matters in this story

Next reads from the same story arc

Kuehn Law Encourages Investors of Quantum Computing Inc. to Contact Law Firm

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

ROSEN, LEADING TRIAL ATTORNEYS, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GRAL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval